REG - C4X Discovery - Exercise of Options, Issue of Equity and TVR

C4X Discovery HoldingsAnnouncement

28/02/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220228:nRSb0970Da&default-theme=true

RNS Number : 0970D  C4X Discovery Holdings PLC  28 February 2022

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Exercise of Options, Issue of Equity and Total Voting Rights

28 February 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, announces it has issued 319,275 ordinary shares of 1p
each in the Company ("New Ordinary Shares") following the exercise of options
by two employees of the Company.

 

Admission and Total Voting Rights

Application has been made for the 319,275 New Ordinary Shares to be admitted
to trading on AIM and dealings are expected to commence on or around 8.00 a.m.
on 4 March 2022. The New Ordinary Shares will rank pari passu with the
existing ordinary shares.

 

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued share
capital now consists of 229,231,972 ordinary shares. Accordingly, the figure
of 229,231,972 may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

Contacts

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500

 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRZZGZZNRNGZZM